VRTS Stock Performance, Insider Transaction and News

VRTS - Virtus Investment Partners, Inc

Market Cap	1.48B	P/E	12.33	EPS this Y	20.50%	Ern Qtrly Grth	-22.70%
Income	121.86M	Forward P/E	7.55	EPS next Y	8.90%	50D Avg Chg	-
Sales	869.44M	PEG	0.25	EPS past 5Y	12.47%	200D Avg Chg	5.00%
Dividend	3.00%	Price/Book	1.77	EPS next 5Y	34.20%	52W High Chg	-18.00%
Recommedations	3.00	Quick Ratio	-	Shares Outstanding	7.13M	52W Low Chg	43.00%
Insider Own	6.08%	ROA	-	Shares Float	6.65M	Beta	1.47
Inst Own	83.97%	ROE	-	Shares Shorted/Prior	84.19K/65.11K	Price	203.28
Gross Margin	40.46%	Profit Margin	14.02%	Avg. Volume	42,809	Target Price	246.00
Oper. Margin	15.85%	Earnings Date	Jul 26	Volume	37,184	Change	-0.98%

Financial Services | Asset Management | United States

About Virtus Investment Partners, Inc

Virtus Investment Partners, Inc. is a publicly owned investment manager. The firm primarily provides its services to individual and institutional clients. It launches separate client focused equity and fixed income portfolios. The firm launches equity, fixed income, and balanced mutual funds for its clients. It invests in the public equity, fixed income, and real estate markets. The firm also invests in exchange traded funds. It employs a multi manager approach for its products. The firm employs quantitative analysis to make its investments. It benchmarks the performance of its portfolios against the S&P 500 Index. The firm conducts in-house research to make its investments. Virtus Investment Partners, Inc. was founded in 1988 and is based in Hartford, Connecticut.

Virtus Investment Partners, Inc News

05/01/24	Virtus Investment Partners, Inc. (NASDAQ:VRTS) Q1 2024 Earnings Call Transcript
05/01/24	Virtus Investment Partners First Quarter 2024 Earnings: EPS: US$4.19 (vs US$5.33 in 1Q 2023)
04/26/24	Virtus Investment Partners Inc (VRTS) Q1 2024 Earnings: Mixed Results Amid Market Challenges
04/26/24	Virtus Investment Partners Announces Financial Results for First Quarter 2024
04/25/24	Should You Buy Virtus Investment Partners (VRTS) Ahead of Earnings?
04/24/24	Will Virtus (VRTS) Beat Estimates Again in Its Next Earnings Report?
04/24/24	Are You Looking for a High-Growth Dividend Stock?
04/24/24	There's A Lot To Like About Virtus Investment Partners' (NYSE:VRTS) Upcoming US$1.90 Dividend
04/22/24	Earnings Preview: Franklin Resources (BEN) Q2 Earnings Expected to Decline
04/19/24	Virtus Investment Partners (VRTS) Earnings Expected to Grow: Should You Buy?
04/19/24	After Plunging -10.64% in 4 Weeks, Here's Why the Trend Might Reverse for Virtus (VRTS)
04/12/24	Virtus Investment Partners to Announce First Quarter 2024 Results on Friday, April 26
04/09/24	Virtus Investment Partners Reports Preliminary March 31, 2024 Assets Under Management
04/08/24	All You Need to Know About Virtus (VRTS) Rating Upgrade to Buy
04/08/24	Why Virtus Investment Partners (VRTS) is a Great Dividend Stock Right Now
03/22/24	Why Virtus Investment Partners (VRTS) is a Top Dividend Stock for Your Portfolio
03/14/24	Lazard's (LAZ) February AUM Improves 1.7% on Upbeat Market
03/13/24	Virtus Investment's (VRTS) February AUM Rises 2.9% Sequentially
03/12/24	Franklin's (BEN) February AUM Benefits From Upbeat Markets
03/11/24	Virtus Investment Partners Reports Preliminary February 29, 2024 Assets Under Management

VRTS Chatroom

epsguid Posted - 04/26/24

$VRTS reported earnings of $5.41, consensus was $5.41 via @eWhispers #epsmeet http://eps.sh/d/vrts

Stock_Titan Posted - 04/26/24

$VRTS Virtus Investment Partners Announces Financial Results for First Quarter 2024 https://www.stocktitan.net/news/VRTS/virtus-investment-partners-announces-financial-results-for-first-07ut9lll1dk5.html

Stock_Titan Posted - 04/17/24

$ZTR $VRTS Virtus Total Return Fund Inc. Discloses Sources of Distribution – Section 19(a) Notice https://www.stocktitan.net/news/ZTR/virtus-total-return-fund-inc-discloses-sources-of-distribution-zckt1efxvwe2.html

Stock_Titan Posted - 04/17/24

$ACV $VRTS Virtus Diversified Income & Convertible Fund Discloses Sources of Distribution – Section 19(a) Notice https://www.stocktitan.net/news/ACV/virtus-diversified-income-amp-convertible-fund-discloses-sources-of-cesd7bkop2aq.html

Stock_Titan Posted - 04/17/24

$AIO $VRTS Virtus Artificial Intelligence & Technology Opportunities Fund Discloses Sources of Distribution – Section 19(a) Notice https://www.stocktitan.net/news/AIO/virtus-artificial-intelligence-amp-technology-opportunities-fund-s9yafk4qwrfs.html

Stock_Titan Posted - 04/12/24

$VRTS Virtus Investment Partners to Announce First Quarter 2024 Results on Friday, April 26 https://www.stocktitan.net/news/VRTS/virtus-investment-partners-to-announce-first-quarter-2024-results-on-5i4p6liksuoj.html

DonCorleone77 Posted - 04/09/24

$VRTS Virtus Investment reports March-end AUM $179.3B Virtus Investment Partners "reported preliminary assets under management of $179.3 billion as of March 31, 2024. The increase from December 31, 2023 primarily reflects market performance and net inflows in retail separate accounts, partially offset by net outflows in institutional accounts and open-end funds. In addition, the company provided services to $2.7 billion of other fee-earning assets, which are not included in assets under management."

Stock_Titan Posted - 04/09/24

$VRTS Virtus Investment Partners Reports Preliminary March 31, 2024 Assets Under Management https://www.stocktitan.net/news/VRTS/virtus-investment-partners-reports-preliminary-march-31-2024-assets-e4zr9jcuffgu.html

Stock_Titan Posted - 03/19/24

RoundBall54 Posted - 03/14/24

From $OCUP website... Jan 4 2024, Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial. “The SPA agreement with the FDA provides a clear regulatory path for phentolamine ophthalmic solution in patients with poor night vision after keratorefractive surgery,” said George Magrath, M.D., M.B.A, M.S, CEO of Ocuphire. “Preparations for the LYNX-2 Phase 3 trial have begun, and we anticipate patient enrollment to begin in the first quarter of 2024.” Under the terms of the November 2022 license agreement, Viatris ($VRTS) will fund the development of phentolamine ophthalmic solution for the treatment of decreased visual acuity under dim (mesopic) light conditions and presbyopia. Ocuphire is eligible to receive a milestone payment upon FDA approvals in these indications. See their press release section for details.

Stock_Titan Posted - 03/11/24

$VRTS Virtus Investment Partners Reports Preliminary February 29, 2024 Assets Under Management https://www.stocktitan.net/news/VRTS/virtus-investment-partners-reports-preliminary-february-29-2024-mo45hp1i2z6d.html